Allogene Therapeutics

162 articles about Allogene Therapeutics

• Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

  5/3/2023

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, provided a corporate update and reported financial results for the quarter ended March 31, 2023.

• Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

  4/26/2023

  Allogene Therapeutics, Inc. today announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2 – 6, 2023 in Chicago, Illinois.

• Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

  4/25/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market.

• Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

  4/20/2023

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.

• Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

  4/17/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR TTM investigational product candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

• Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

  4/13/2023

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that it will participate in four upcoming investor conferences.

• Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

  3/30/2023

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, published its 2022 annual ESG report.

• Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

  3/14/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR T candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in April in Orlando, Florida.

• Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

  3/2/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences.

• Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

  3/1/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a case review in Molecular Therapy of the single patient treated with ALLO-501A who presented with a chromosomal rearrangement.

• Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  2/28/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2022.

• Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

  2/21/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and year-end 2022 financial results on Tuesday, February 28, 2023, after the close of the market.

• Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

  2/1/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation DaggerTM platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada.

• Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

  1/25/2023

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC).

• Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

  1/24/2023

  Allogene Therapeutics, Inc. today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) multiple myeloma (MM) has been published in Nature Medicine.

• Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences - Jan 17, 2023

  1/17/2023

  Allogene Therapeutics, Inc. announced that it will participate in two upcoming investor conferences.

• Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Allogene Therapeutics, Inc. today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:45 p.m. Pacific Time.

• Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

  1/3/2023

  Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the appointment of Zachary J. Roberts M.D., Ph.D. to Executive Vice President of Research and Development.

• Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

  11/29/2022

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances from three clinical stage AlloCAR T programs.

• Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

  11/10/2022

  Allogene Therapeutics, Inc. today presented pre-clinical data on a novel approach to immune “cloaking” designed to protect AlloCAR T™ cells from rapid host rejection.